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OBJECTIVES: A range of treatments have been used for late stage metastatic mela-
noma including chemotherapy, immunotherapy drugs (given alone or in combination), 
palliative surgery and radiation therapy. Nevertheless, current treatment practices in 
Australia for patients with advanced melanoma are poorly deﬁ ned. As such, a retro-
spective longitudinal survey was conducted to gain an insight into the treatments 
currently used in this patient group. METHODS: Three Australian public hospitals 
provided patient level data. Inclusion criteria encompassed patients with a history of 
an unresectable stage III/IV melanoma (advanced melanoma) at initial diagnosis and 
had at least 6 months follow-up between January 1, 2005 and December 31, 2006. 
Information on demographics, disease characteristics, adverse events, survival and 
treatment history was obtained from medical records of all eligible patients. Descrip-
tive statistics were performed for the four most frequently used ﬁ rst-line treatments. 
Survival estimates were assessed using Kaplan Meier methods. Comparisons of sur-
vival by treatment choice were assessed using a log-rank test. RESULTS: In total, 51 
patients were recruited with a mean age of 61.6 years and the majority Caucasian 
(96.1%). Twelve patients (23.5%) were stage III and 23 (45.1%) stage IV. Speciﬁ c 
staging of remaining 16 (31.4%) advanced melanoma patients was unknown. The 
main ﬁ rst-line treatments were dacarbazine (17.6%), fotemustine (15.7%), radio-
therapy (23.5%), and surgery (23.5%). Patients treated with surgery were younger 
and mainly stage IV at diagnosis. Surgery was associated with longer survival (P = 
0.0016); however, a causal relationship cannot be inferred. There was a tendency for 
fewer patients to receive surgery for second-line treatment with slightly more receiving 
radiotherapy. Chemotherapy was associated with nausea while hematological events 
were common in fotemustine patients. CONCLUSIONS: This study found that four 
main treatments are used for unresectable stage III/IV melanoma: dacarbazine, fote-
mustine, radiotherapy and surgery. The data suggests that surgery was associated with 
longer overall survival compared to the alternative therapies. 
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OBJECTIVES: To measure economic consequences of NBP (Butylphthalide) for acute 
ischemic stroke in China. METHODS: A multi-center, randomized, double-blind 
control study was conducted, 220 patients were admitted into the treatment group 
and control group, the main regimen is A1 (Butylphthalide sodium chloride injection 
and Butylphthalide sodium chloride capsule), A2 (Butylphthalide sodium chloride 
injection), B (Ozagrel injection). We explored the MRS (modiﬁ ed Rankin score) to 
establish Markov state transition model, with six different health states. The cost and 
effectiveness data were come from the studies based on Chinese acute ischemic stroke 
studies. Based on transferred Markov matrix, we will obtain the time period for 
disease steady-state and predict long-term costs and cost-effectiveness from the 
patient’s perspective. RESULTS: A1 group reached the steady state ﬁ rst, ﬁ ve cycles 
(10 months), A2 and B group were behind a period. The steady state cost of A1 group 
involved 79,396.90 yuan, more than A2 group by 19,379.54 yuan, and 85,806.71 
yuan for B group, compared with the extension days with no obvious signiﬁ cant. At 
a steady state, the cost-effectiveness ratio of A1 Group’s health state was 86.3 thou-
sand yuan, A2 group 82.1 thousand yuan and B group 96.4 thousand yuan, Thus, 
economic results of A group (A1 and A2) were better than B group, A2 group slightly 
better than A1 group, but given the time to reach a steady state, the A1 group had 
more advantages of economic effects. CONCLUSIONS: Based on the results of this 
model-based economic analysis, A1 strategy was the most cost-effective option in 
comparisons with A2 and B strategies for acute ischemic stroke in China. 
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OBJECTIVES: Therapeutic interchange is not a well-accepted clinical practice in the 
medical society in Asia. Clinic blood pressure readings, patients’ tolerance, and cost-
effectiveness were used as measures to evaluate the impact of a therapeutic interchange 
program implemented at a medical center in Taiwan. METHODS: Taipei Medical 
University-Wan Fang Medical Center initiated a therapeutic interchange program 
involving angiotensin II receptor blockers (ARBs). Data were retrospectively collected 
for 444 hypertensive outpatients who were converted from other ARBs to candesartan. 
Evaluation of therapeutic efﬁ cacy, adverse effects associated with therapy, and drug 
costs was conducted before and after the program implementation. RESULTS: Patients 
who were converted to candesartan experienced no statistically signiﬁ cant differences 
in blood pressure, and the average number of antihypertensive agents used per patient 
remained unchanged. A direct cost savings of US$62,237 was estimated for the 444 
patients studied, which amounted to a savings of more than US$730,000 annually for 
all outpatients using ARBs. Only 3.15% of patients developed ADRs potentially 
related to the candesartan and none required hospitalization. CONCLUSIONS: Based 
on the results of this retrospective chart review, the present therapeutic interchange 
program was successfully developed and implemented. This is the ﬁ rst study to estab-
lish the positive impact of a well-run ARBs therapeutic interchange program in 
Taiwan. 
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OBJECTIVES: To compare the efﬁ cacy and safety of several different anticoagulant 
therapies in high-risk surgical patients using a mixed treatment comparison (MTC) 
approach. METHODS: A manual literature search for randomized double blind 
controlled trials (RDBCTs) was undertaken that compared any two of the following 
agents: enoxaparin, rivaroxaban, unfractionated heparin (UFH) or placebo and 
reported rates of venous thromboembolism (VTE) in patients undergoing total hip 
replacement, hip fracture surgery, total knee replacement and general surgery. Bayes-
ian methods of MTC meta-analysis were applied to synthesize data from 31 RDBCTs. 
Safety data (deﬁ ned as major hemorrhage) were extracted when available. Patients 
received prophylaxis for up to 15 days, or extended therapy up to 35 days post-
surgery. RESULTS: All treatments were compared to placebo using the Odds Ratio 
as a measure of efﬁ cacy. When compared to placebo, the incidence of VTE was 
reduced by ≥50% with prophylactic therapy post-hip surgery; patients undergoing 
extended prophylaxis with enoxaparin or rivaroxaban received the greatest beneﬁ t, 
with a reduction in the risk of VTE of 87% or 95% respectively. Prophylaxis also 
reduced the incidence of VTE after knee surgery by ≥80%; patients treated with 
enoxaparin or rivaroxaban were 87% or 92% less likely to experience VTE, respec-
tively, when compared to placebo. Prophylaxis after general surgery signiﬁ cantly 
reduced the risk of VTE over placebo by ≥76%. The risk of major hemorrhage was 
highest with UFH, followed by rivaroxaban and enoxaparin. CONCLUSIONS: The 
MTC approach resulted in a comprehensive examination of the effect of thrombopro-
phylaxis on the rate of VTE and major hemorrhage in high-risk surgery. Upon examin-
ing the body of clinical data, the evidence is clear: thromboprophylaxis is highly 
effective at preventing VTE in patients undergoing high-risk surgery. When compared 
with rivaroxaban and UFH, prophylaxis with enoxaparin resulted in similar and lower 
incidence of VTE respectively, with less major hemorrhage. 
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OBJECTIVES: Pretreatment with angiotensin-converting enzyme inhibitors (ACEI) 
has shown promising results in decreasing the incidence and the severity of ischemic 
stroke in populations at risk, and in improving ischemic stroke outcomes. The aims 
of this study were to investigate the impact of ACEI use before ischemic stroke onset 
on in-hospital mortality and to identify the independent predictors of in-hospital 
mortality among ischemic stroke patients. METHODS: It is a retrospective cohort 
study of all acute ischemic stroke patients admitted to a 1200-bed hospital located in 
northern Malaysia from June 1, 2008 to November 30, 2008. Data were collected 
from medical records and included demographic information, diagnostic information, 
risk factors, previous ACEI use and vital discharge status. SPSS version 15 was used 
for data analysis. RESULTS: Overall, 327 acute ischemic stroke patients were studied, 
of which 119 (36.4%) had documented previous ACEI use. During the study period, 
52 (15.9%) of the acute ischemic stroke patients died in hospital. In-hospital mortality 
was signiﬁ cantly lower among patients who were on ACEI before the attack (P = 
0.002). The independent predictors for in-hospital mortality among ischemic stroke 
patients were the presence of diabetes mellitus (P = 0.023), renal impairment (P < 
0.001) and heart failure (P = 0.007). Moreover, prior use of ACEI was an independent 
predictor for survival after ischemic stroke attack (P < 0.001). CONCLUSIONS: This 
study provides evidence that the prophylactic administration of ACEI is a potential 
life-saving strategy. Furthermore, knowledge of in-hospital mortality predictors is 
necessary to improve survival rate after acute ischemic stroke attack. 
